1. Home
  2. ENOV vs ANAB Comparison

ENOV vs ANAB Comparison

Compare ENOV & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovis Corporation

ENOV

Enovis Corporation

N/A

Current Price

$23.87

Market Cap

1.5B

Sector

Industrials

ML Signal

N/A

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$57.66

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENOV
ANAB
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
ENOV
ANAB
Price
$23.87
$57.66
Analyst Decision
Strong Buy
Buy
Analyst Count
9
12
Target Price
$47.38
$71.67
AVG Volume (30 Days)
1.2M
636.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$6.36
N/A
Revenue Next Year
$5.31
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$19.14
$17.11
52 Week High
$34.28
$73.30

Technical Indicators

Market Signals
Indicator
ENOV
ANAB
Relative Strength Index (RSI) 41.38 52.22
Support Level $21.02 $53.46
Resistance Level $24.08 $57.70
Average True Range (ATR) 1.50 2.45
MACD -0.78 0.60
Stochastic Oscillator 3.05 82.21

Price Performance

Historical Comparison
ENOV
ANAB

About ENOV Enovis Corporation

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: